Salivary gland malignancies remain a subject of misclassification and broad categorization especially in the analysis of retrospective clinical data and in prospective clinical trial design. This is largely due to their rarity and lack of objective clinico-pathologic criteria. Recently, specific translocation breakpoints have been mapped with the discovery of new fusion oncogenes that underlie the etiology of these tumors and define the most common subtypes. Therefore, in response to the new emerging genetic and biological data the International Conference on Malignant Salivary Gland Tumors was implemented to bring together investigators from different disciplines, different departments, and from different countries to catalyze new collaborations and therapeutic strategies, to spur the interest and mentorship of new young investigators, and to highlight the clinical implications of these new research accomplishments.
The 4th International Conference on Malignant Salivary Gland Tumors will take place on October 19-20, 2017 at the University of Florida Cancer/Genetics Research Complex. The conference will focus on the primary goal of bringing together clinicians and basic scientists to foster new ideas, experiments, and clinical trial opportunities for patients with salivary gland cancers. There are new genetically engineered mouse models largely unpublished for both adenoid cystic cancer and for mucoepidermoid cancer and this is an important time to bring together all participants to maximize collaborations and accelerate progress. There are new opportunities for studying salivary gland development and stem cells for understanding tumorigenesis and resistance to cancer treatments. This conference has a history and track record for inclusion of young investigators and fostering mentorship, collaborations, and sharing of reagents and patient related resources that is highly regarded among participants.